- \n
- FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches<\/i><\/b><\/li>\n
- Achieved Latest FY2025 Management Guidance<\/i><\/b><\/li>\n
- Takeda is Entering a New Era & Transforming for Growth Acceleration<\/i><\/b><\/li>\n<\/ul>\n
\n\u00a0<\/p>\n
OSAKA, Japan–(BUSINESS WIRE<\/a>)–
\nTakeda (TOKYO:4502\/NYSE:TAK<\/a><\/span>) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth.<\/p>\nKey Highlights for FY2025<\/b><\/p>\n
- \n
- \nRevenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE\u00ae which was partially mitigated by Growth and Launch Products. On a Core basis, Revenue decreased by 2.6% at Constant Exchange Rate (CER).<\/p>\n<\/li>\n
- \nCore Operating Profit increased by 0.8% YoY at AER and declined by 0.9% at CER, protected by OPEX savings, while still investing for growth.<\/p>\n<\/li>\n
- \nReported Operating Profit increased by 19.3% YoY at AER, also reflecting a step-down in amortization expenses for VYVANSE and lower restructuring expenses.<\/p>\n<\/li>\n
- \nCore EPS increased by 5.2% YoY at AER and by 3.1% at CER, while reported EPS increased by 78.1% YoY.<\/p>\n<\/li>\n
- \nAdjusted Free Cash Flow amounted to JPY 684.5 billion, in line with forecast, and the Company ended fiscal year with strong cash balance.<\/p>\n<\/li>\n
- \nDelivered key milestones for oveporexton, rusfertide, and zasocitinib, with positive Phase 3 readouts; completed regulatory submissions for oveporexton and rusfertide, and launch preparations underway.<\/p>\n<\/li>\n<\/ul>\n
Takeda Chief Executive Officer (CEO)-elect, Julie Kim, commented:
\n
<\/b>\u201cFY2025 was a pivotal year, validating the strength of our execution against demanding development and regulatory milestones, the resilience of our commercial portfolio and our strong position with three major launches planned in the next 12 months and the most robust late-stage pipeline in our history. Our growth roadmap is built around two strategic horizons: transforming for growth through near-term launches and strengthening competitiveness and accelerating growth by transitioning to a new cohort of blockbuster brands, together positioning us for long-term profitable growth and patient impact.\u201d<\/p>\nTakeda Chief Financial Officer, Milano Furuta, commented:
\n
<\/b>\u201cIn FY2025, despite topline headwinds, we delivered solid profit and cash flow through disciplined cost control, while directing growth investment toward new product launches and the pipeline. In FY2026, we will continue to focus on transforming operations and protecting profitability while delivering successful launches and advancing our pipeline. Strong cash flow generation and deleveraging will support long-term investment for growth acceleration and ensure competitive returns for our shareholders.\u201d<\/p>\nFull-year FY2026 Forecast and Guidance
\n
<\/b>Based on the current business outlook and planned investment profile, Takeda issued the following FY2026 forecast and management guidance.<\/p>\n
- Achieved Latest FY2025 Management Guidance<\/i><\/b><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260510786927\/en\/791321\/3\/logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n